Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S102000, C546S110000
Reexamination Certificate
active
10501474
ABSTRACT:
This invention pertains to certain acridone and acridine compounds of the formula which inhibit telomerase, regulate cell proliferation, etc., and/or treat cancer, proliferative conditions, etc.: wherein either: (a) K is ═O, L is —H, alpha single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1is a 2- or 3-substituent; J2is a 6- or 7-substituent; J1and J2are each a group of the formula —N(RN)—W, wherein: RNis a nitrogen substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and, W is C1-17alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and, wherein, when K is a 9-substituent, K is a group of the formula —N(RN)—Q, wherein: RNis an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, etc., and/or in the treatment of cancer, proliferative conditions, etc.
REFERENCES:
patent: 2003/0207909 (2003-11-01), Neidle
patent: 488 890 (1930-01-01), None
patent: WO 02/08193 (2002-01-01), None
McConnaughie et al., “Novel Acridine-Triazenes as Prototype Combilexins:Synthesis, DNA Binding, and Biological Activity”, Journal of medicinal Chemistry, vol. 38, pp. 3488-3501.
Bears et al., “Telomere maintenance mechanisms as a target for drug development”, Oncogene, vol. 19, pp. 6632-6641.
Vietor et al., “On the significance of telomerase activity in human malignant glima cell”, European Journal of Pharmacology, vol. 407, pp. 27-37.
Alberti, P., et al., 2002, “Benzoindoloquinolines Interact with DNA Tetraplexes and Inhibit Telomerase,”Biorganic&Medicinal Chemistry Letters, vol. 12, pp. 1071-1074.
Autexier, C., 1999, “Telomerase as a Possible Target for Anticancer Therapy,”Chemistry&Biology, Nov. 1999, vol. 6, pp. R299-R303.
Bogert, M.T., et al., 1930, “Researchers in the Acridine Series. The Synthesis of Isomers of Proflavine and of Neutral Acriflavine,”Collect. Czech. Chem. Comm., vol. 2, pp. 383-395.
Bostock-Smith, C.E., et al., 1999, “Molecular Recognition between a New Pentacyclic Acridinium Salt and DNA Sequences Investigated by Optical Spectroscopic Techniques, Proton Nuclear Magnetic Resonance Spectroscopy, and Molecular Modeling,”Biochemistry, vol. 38, No. 21, pp. 6723-6731.
Cain, B.F., et al., 1974, “Potential Antitumor Agents. 14. Acridylmethanesulfonanilides,”J. Med. Chem., vol. 17, No. 9, pp. 922-930.
Cain, B.F., et al., 1976, “Potential Antitumor Agents. 17. 9-Anilino-10-methylacridinium salts,”J. Med. Chem., vol. 19, No. 6, pp. 772-777.
Cain, B.F., et al., 1976, “Potential Antitumor Agents. 19. Multiply Substituted 4′-(9-Acridinylamino)methanesulfonanilides,”J. Med. Chem., vol. 19, No. 9, pp. 1124-1129.
Carrasco, C., et al., 2002, “Tight Binding of te Antitumor Drug Ditercalcinium to Quaduplex DNA,”ChemBioChem, vol. 3, pp. 1235-1241.
Corey, D.R., 2002, “Telomerase Inhibition, Oligonucleotides, and Clinical Trials,”Oncogene, vol. 21, pp. 631-637.
Denny, W.A., et al., 1982, “Potential Antitumor Agents. 36. Quantitative Relationships between Experimental Antitumour Activity, Toxicity, and Structure for the General Class of 9-Anilinoacridine Antitumor Agents,”J. Med. Chem., vol. 25, pp. 276-315.
Gamage, S.A., et al., 1994, “Synthesis and in Vitro Evaluation of 9-Anilino-3,6-diaminoacridines Active Against a Multidrug Resistant Strain of the Malaria Parasite Plasmodium falciparum,”J. Med. Chem., vol. 37, No. 10, pp. 1486-1494.
Gimenez-Arnau, E. et al., 1998, “Antitumour Polycyclic Acridines, Part 2,”Anti-Cancer Drug Design, vol. 13, pp. 125-143.
Gimenez-Arnau, E., et al., 1998, “Antitumour Polycyclic Acridines, Part 4,”Anti-Cancer Drug Design, vol. 13, pp. 431-451.
Goldberg, A.A. and Kelly, W., 1946, “29. Synthesis of Diaminoacridines. Part I,”J. Chem.Soc., p. 102-111.
Goldstein, H., and de Simo, M., 1927, “Quelques derives de l'acide phenyl-anthranilique III,”Helv. Chim. Acta., vol. 10, p. 603-606.
Gomez, D., et al., 2002, “Detection of Telomerase Inhibitors Based on G-Quadruplex Ligands by a Modified Telomeric Repeat Amplification Protocol Assay,”Cancer Research, vol. 62, pp. 3365-3368.
Gowan, S.M., et al., 2002, “A G-Quadruplex-Interactive Potent Small-Molecule Inhibitor of Telomerase Exhibiting in Vitro and in Vivo Antitumour Activity,”Molecular Pharmacology, vol. 61, No. 5, pp. 1154-1162.
Hagan, D.H., et al., 1997, “Antitumour Polycyclic Acridines, Part 1,”J. Chem. Soc., Perkin Trans. 1, pp. 2739-2746.
Hagan, D.H., et al., 1998, “Antitumour Polycyclic Acridines, Part 3,”J. Chem. Soc., Perkin Trans. 1, p. 915-923.
Harrison, R.J., et al., 1999, “Human Telomerase Inhibition by Substituted Acridine Derivatives,”Bioorganic&Medicinal Chemistry Letters, vol. 9, pp. 2463-2468.
Herbert, B.-S., et al., 2001, “Telomerase and Breast Cancer,”Breast Cancer Research, vol. 3, pp. 146-149.
Hoffmann, S., et al., 1986, “Synthese bisbasisch-substituierter Acridine als potentielle Nucleinsaureelfecktoren,”Zeitschrift fur Chemie, vol. 26, No. 9, pp. 331-332.
Julino, M., et al., 1998, “Antitumour Polycyclic Acridines, Part 5,”J. Chem. Soc., Perkin Trans. 1, pp. 1677-1684.
Kern, J.T., et al., 2002, “The Relationship between Ligand Aggregation and G-Quadruplex DNA Selectivity in a Series of 3,4,9,10-Perylenetetracarboxylic Acid Diimides,”Biochemistry, vol. 41, pp. 11379-11389.
Kim, M.-Y., et al., 2002, “Telomestatin, a Potent Telomerase Inhibitor That Interacts Quite Specifically with the Human Telomeric Intramolecular G-Quadruplex,”J. Amer. Chem. Soc., vol. 124, No. 10, pp. 2098-2099.
Kim, N.W., et al., 1994, “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”,Science, vol. 266, pp. 2011-2015.
Klopman, G., et al., 1987, “Computer-Automated Structure Evaluation of Antiluekemic 9-Anilinoacridines,”Molecular Pharmacology, vol. 31, pp. 457-476.
Korolev, B.A., et al., 1976, “Preparation of 2-Aminoacridan by the Reduction of 2-Amino-9-Acridanone with Biborane,”J. Gen. Chem. USSR(Engl. Trans.) , vol. 46, pp. 2250-2252.
Korolev, B.A., et al., 1977, “Acridines. II. Selective Reductionof Nitro Derivatives of 2-Amino-9-Acridanone with Diborane,”J. Gen. Chem. USSR(Engl. Trans.) , vol. 47, pp. 2118-2122.
Li, J.-L., et al., 2001, “Inhibition of the Bloom's and Werner's Syndrome Helicases by G-Quadruplex Interacting Ligands”,Biochemistry, vol. 40, pp. 15194-15202.
Lorente, A., et al., 1996, “Syntheses of Imidazole-Acridine Conjugates as Ribonuclease A Mimics,”Tetrahedron Letters, vol. 37, No. 25, pp. 4417-4420.
Matsumura, K., 1929, “The Synthesis of Certain Acridine Compounds,”J. Amer. Chem. Soc., vol. 51, pp. 816-820.
Mergny, J.-L., et al., 2002, “Natural and Pharmacological Regulation of Telomerase,”Nucleic Acids Research, vol. 30, No. 4, pp. 839-865.
Moisan, M., et al., 1993, “New α, ω-Diamino Mono- and Di-Bridged Acridine Dimers,”Monatshefte fur Chemie, vol. 124, pp. 23-35.
Neidle, S., et al., 1999, “Telomerase as an Anti-Cancer Target: Current Status and Future Prospects,”Anti-Cancer Drug Design, vol. 14, pp. 341-347.
Neidle, S., et al.
Gowan Sharon Michele
Harrison Richard John
Kelland Lloyd Royston
Neidle Stephen
Read Martin Anthony
Cancer Research Technology Limited
Nixon & Vanderhye P.C.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
Therapeutic acridone and acridine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic acridone and acridine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic acridone and acridine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734824